iBio announces offering of common stock, warrants

iBio announced it intends to offer and sell, subject to market and other conditions, shares of its common stock and Series A and Series B warrants to purchase shares of common stock in an underwritten public offering. The company intends to use the net proceeds from the offering primarily for operating costs, including for research and development and other trial preparation expenses in addition to working capital needs and for other general corporate purposes, which may include retention and severance payments to certain of our employees or former employees and principal payments pursuant to the terms of its amended Credit Agreement. H.C. Wainwright & Co. is acting as sole book-running manager for the proposed public offering.